Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab as first-line therapy in early active axial spondyloarthritis
2008-000982-51Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2009
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) and spondyloarthritis (SpA) comparing Infliximab + naproxen with Placebo + naproxen (2 arms). Primary endpoint: ASAS partial remission at Week 28. Started Feb 2009; status: completed.
02
Drugs
infliximabnaproxen
03
Conditions
axial spondyloarthritis (axSpA)spondyloarthritis (SpA)
Beyond the preview
Go deeper on 2008-000982-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000982-51.